SecBot SecBot
DEFA14A ·Filed Apr 7, 2026

PASG

Passage BIO, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed7mo ago SEC0001104659-26-040131
Proxy solicitation materials
Actionable Insight • Neutral

This is a standard proxy filing for an annual shareholder meeting. There are no material financial changes or strategic shifts. Shareholders should review the proxy statement for details on director qualifications and compensation matters, but no significant market impact is expected.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.22
T+0 close · Apr 7, 2026 · via day close
Latest settled
−43.03%
T+60 · $4.68
Vs SPY
−56.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $8.22entry
  2. T+1 · 7mo ago +13.09%α +10.55% · $9.29
  3. T+5 · 7mo ago +32.20%α +26.87% · $10.86
  4. T+20 · 7mo ago −44.37%α −54.15% · $4.57
  5. T+60 · 5mo ago −43.03%α −56.30% · $4.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, which includes the election of two Class III directors, ratification of its independent auditor, and approval of executive compensation. This is a routine corporate governance filing.

Key Financial Metrics

Vote
director election
Meeting
2026-05-19
Seats Contested
2

Key Facts

  • Election of two Class III directors: Athena Countouriotis, M.D. and Sandip Kapadia
  • Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026
  • Approval of executive officer compensation on a non-binding advisory basis
  • Approval of frequency for future advisory votes on executive compensation

Financial Impact

Routine corporate governance with no direct financial impact

governanceexecutive compensation

Risk Factors

  • None disclosed in this filing
  • Standard risks associated with any biotechnology company

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-040131
Document: 0001104659-26-040131-index-headers.html0001104659-26-040131
Document: 0001104659-26-040131-index.html0001104659-26-040131
Document: 0001104659-26-040131.txt0001104659-26-040131

Track record

15 reports on PASG

Performance horizon

2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026